

Latin America Viral Vector Manufacturing Market Report and Forecast 2024-2032

Market Report | 2024-06-26 | 140 pages | EMR Inc.

AVAILABLE LICENSES:

- Single User License \$3999.00
- Five User License \$5299.00
- Corporate License \$6299.00

Report description:

Latin America Viral Vector Manufacturing Market Report and Forecast 2024-2032

Latin America Viral Vector Manufacturing Market Size

The global viral vector manufacturing market was valued at USD 2.6 billion in 2023, with Latin America holding a significant market share. It is expected to grow at a CAGR of 19.74% during the forecast period of 2024-2032 and attain a market value of USD 13.5 billion by 2032, driven by the increasing awareness about gene therapy across the region.

Latin America Viral Vector Manufacturing Market Outlook

- In March 2024, the National Health Surveillance Agency (Anvisa) of Brazil approved the world's first gene therapy Biomarin's Roctavian for severe adults with hemophilia A. This approval may contribute to increased adoption of viral vector manufacturing in the region.

- The market is witnessing surge in mergers and acquisitions, projected to boost the market value in the forecast period. In March 2024, a foundation from the Brazilian government's Ministry of Health, and Caring Cross, anon-profit organisation collaborated to develop local manufacturing of (CAR)-T cell and stem cell gene therapies for oncology, infectious, and genetic diseases in Brazil.

- Brazil has seen a significant increase in the number of dengue cases over the past four years. As of 2024, there have been 232,900 reported cases and 161 deaths. This has created a demand for the development of new vaccines, leading to growth in the market.

Latin America Viral Vector Manufacturing Market Analysis

Viral vectors are efficient gene transfer vehicles that are commonly used by molecular biologists to manipulate a specific cell type or tissue for certain therapeutic purposes. Regulatory approvals play a pivotal role in the distribution of therapeutics, and diagnostics in the market among other healthcare products and services while adding credibility at the same time. The market is

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

propelled by the approvals of newly developed gene therapies by the regulatory authorities in the region. For instance, in March 2024, the National Health Surveillance Agency (Anvisa) of Brazil approved world's first gene therapy Biomarin's Roctavian (valoctocogene roxaparvovec) for severe hemophilia A. The approval is expected to foster increased investments in local manufacturing capabilities and technologies, thereby, enhancing the Latin America viral vector manufacturing market share.

The market is witnessing strategic collaborations, which is supporting viral vector manufacturing and its application in various healthcare domains. For instance, in March 2024, a collaboration was announced by the Brazilian government's Ministry of Health foundation, Fundacao Oswaldo Cruz (Fiocruz) and Caring Cross, to support the advancement of local manufacturing of chimeric antigen receptor (CAR)-T cell and stem cell gene therapies for oncology, infectious, and genetic diseases in Brazil. This also includes CAR-T cell therapies for leukemia, lymphoma, and HIV infection. The Caring Cross is a non-profit organisation, aimed at improving the development of innovative medicines and providing access to advanced medicinal. Such partnerships are expected to boost the Latin America viral vector manufacturing market growth in the forecast period.

The market demand is also projected to be positively impacted by the rising infectious diseases in the region. For instance, Buenos Aires has registered around 232,900 dengue cases and 161 deaths within the first 8 weeks of 2024. This outbreak has been considered the worst in 4 years. Increasing cases of dengue in Argentina create a pressing need to develop a vaccine in the region to overcome this outbreak. This will contribute to the increased demand for vaccines and therapeutics in the region, propelling the Latin America viral vector manufacturing market size. The rising demand can attract investors and expansions in the facilities needed for the production of viral vectors, which are crucial for manufacturing certain types of vaccines. As a result, the market is poised to be driven by the pressing need to develop more advanced technologies to assist vaccine development.

Latin America Viral Vector Manufacturing Market Segmentation??
The report offers a detailed analysis of the market based on the following segments:

- Market Breakup by Type
- ? Adenoviral Vectors
 - ? Adeno-Associated Viral (AAV) Vectors
 - ? Lentiviral Vectors
 - ? Retroviral Vectors
 - ? Others

- Market Breakup by Application
- ? Gene Therapy
 - ? Cell Therapy
 - ? Others
- Market Breakup by Therapeutic Area
- ? Oncological Disorders
 - ? Neurological Disorders
 - ? Metabolic Disorders
 - ? Immunological Disorders
 - ? Others

- Market Breakup by End User
- ? Research Organizations
 - ? Biotech and Pharmaceutical Companies
 - ? Others

Market Breakup by Country

■ Brazil

■ Argentina

■ Mexico

■ Others

Leading Players in the Latin America Viral Vector Manufacturing Market

The key features of the market report include patent analysis, grants analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:?

■ Lonza Group AG

■ Merck KGaA

■ Thermo Fisher Scientific Inc.

■ Catalent, Inc.

■ Danaher Corporation

■ Sartorius AG

■ Fujifilm Group

■ Novartis AG

■ Charles River Laboratories

■ Laboratorios Liomont

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.?

FAQs

■ What was the Latin America viral vector manufacturing market forecast outlook in 2024-2032?

The Latin America viral vector manufacturing market is expected to be driven by the rising demand for global market, which is anticipated to grow at a CAGR of 19.7% during the forecast period of 2024-2032 and is likely to reach a market value of USD 8.1 billion by 2032.

■ What are the major factors aiding the Latin America viral vector manufacturing market demand? ?

The market is driven by the increasing awareness of biotechnology and gene therapy for the treatment of several diseases.

■ What are the major Latin America viral vector manufacturing market trends??

The market growth is influenced by increasing collaboration and partnerships in the region. For instance, in March 2024, Caring Cross and Fiocruz collaborated to improve access to cell and gene therapies in the region.

■ What are the various types of viral vector manufacturing?

Various types include adenoviral vectors, adeno-associated viral (AAV) vectors, lentiviral vectors, retroviral vectors, and others.

■ What are the various applications of viral vector manufacturing?

Viral vector manufacturing has applications in gene therapy, cell therapy, and vaccines.

■ What are the therapeutic areas of viral vector manufacturing?

Therapeutic areas include oncological disorders, neurological disorders, metabolic disorders, immunological disorders, and others.

■ Who are the end users in the market?

End users in the market include research organizations, biotech and pharmaceutical companies, and others.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

-□What is the market segmentation by country??

The market segmentation by countries includes Brazil, Argentina, Mexico, and others.

-□Who are the key players in the Latin America viral vector manufacturing market?

The key players in the market are Lonza Group AG, Merck KGaA, Thermo Fisher Scientific Inc., Catalent, Inc., Danaher Corporation, Sartorius AG, Fujifilm Group, Novartis AG, Charles River Laboratories, and Laboratorios Liomont.

Meta description

The Latin America viral vector manufacturing market size is poised for growth, driven by the expansion of the global market, which was valued at USD 2.6 billion in 2023 and is projected to grow at a CAGR of 19.74% during the forecast period of 2024-2032.

Table of Contents:

- 1 Preface
 - 1.1 Objectives of the Study
 - 1.2 Key Assumptions
 - 1.3 Report Coverage - Key Segmentation and Scope
 - 1.4 Research Methodology
- 2 Executive Summary
- 3 Latin America Viral Vector Manufacturing Market Overview
 - 3.1 Latin America Viral Vector Manufacturing Market Historical Value (2017-2023)
 - 3.2 Latin America Viral Vector Manufacturing Market Forecast Value (2024-2032)
- 4 Latin America Viral Vector Manufacturing Market Landscape*
 - 4.1 Latin America Viral Vector Manufacturing: Developers Landscape
 - 4.1.1 Analysis by Year of Establishment
 - 4.1.2 Analysis by Company Size
 - 4.1.3 Analysis by Region
 - 4.2 Latin America Viral Vector Manufacturing: Product Landscape
 - 4.2.1 Analysis by Type
 - 4.2.2 Analysis by Technology
- 5 Latin America Viral Vector Manufacturing Market Dynamics
 - 5.1 Market Drivers and Constraints
 - 5.2 SWOT Analysis
 - 5.2.1 Strengths
 - 5.2.2 Weaknesses
 - 5.2.3 Opportunities
 - 5.2.4 Threats
 - 5.3 Porter's Five Forces Model
 - 5.3.1 Bargaining Power of Suppliers
 - 5.3.2 Bargaining Power of Buyers
 - 5.3.3 Threat of New Entrants
 - 5.3.4 Threat of Substitutes
 - 5.3.5 Degree of Rivalry
 - 5.4 Key Demand Indicators
 - 5.5 Key Price Indicators
 - 5.6 Industry Events, Initiatives, and Trends
 - 5.7 Value Chain Analysis

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 6 Latin America Viral Vector Manufacturing Market Segmentation (2017-2032)
 - 6.1 Latin America Viral Vector Manufacturing Market (2017-2032) by Type
 - 6.1.1 Market Overview
 - 6.1.2 Adenoviral Vectors
 - 6.1.3 Adeno-Associated Viral (AAV) Vectors
 - 6.1.4 Lentiviral Vectors
 - 6.1.5 Retroviral Vectors
 - 6.1.6 Others
 - 6.2 Latin America Viral Vector Manufacturing Market (2017-2032) by Application
 - 6.2.1 Market Overview
 - 6.2.2 Gene Therapy
 - 6.2.3 Cell Therapy
 - 6.2.4 Vaccines
 - 6.3 Latin America Viral Vector Manufacturing Market (2017-2032) by Therapeutic Area
 - 6.3.1 Market Overview
 - 6.3.2 Oncological Disorders
 - 6.3.3 Neurological Disorders
 - 6.3.4 Metabolic Disorders
 - 6.3.5 Immunological Disorders
 - 6.3.6 Others
 - 6.4 Latin America Viral Vector Manufacturing Market (2017-2032) by End User
 - 6.4.1 Market Overview
 - 6.4.2 Research Organizations
 - 6.4.3 Biotech and Pharmaceutical Companies
 - 6.4.4 Others
 - 6.5 Latin America Viral Vector Manufacturing Market (2017-2032) by Country
 - 6.5.1 Market Overview
 - 6.5.2 Brazil
 - 6.5.3 Argentina
 - 6.5.4 Mexico
 - 6.5.5 Others
- 7 Brazil Viral Vector Manufacturing Market (2017-2032)
 - 7.1 Brazil Viral Vector Manufacturing Market (2017-2032) by Type
 - 7.1.1 Market Overview
 - 7.1.2 Adenoviral Vectors
 - 7.1.3 Adeno-Associated Viral (AAV) Vectors
 - 7.1.4 Lentiviral Vectors
 - 7.1.5 Retroviral Vectors
 - 7.1.6 Others
 - 7.2 Brazil Viral Vector Manufacturing Market (2017-2032) by Application
 - 7.2.1 Market Overview
 - 7.2.2 Gene Therapy
 - 7.2.3 Cell Therapy
 - 7.2.4 Vaccines
 - 7.3 Brazil Viral Vector Manufacturing Market (2017-2032) by Therapeutic Area
 - 7.3.1 Market Overview
 - 7.3.2 Oncological Disorders

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 7.3.3 Neurological Disorders
- 7.3.4 Metabolic Disorders
- 7.3.5 Immunological Disorders
- 7.3.6 Others
- 7.4 Brazil Viral Vector Manufacturing Market (2017-2032) by End User
 - 7.4.1 Market Overview
 - 7.4.2 Research Organizations
 - 7.4.3 Biotech and Pharmaceutical Companies
 - 7.4.4 Others
- 8 Argentina Viral Vector Manufacturing Market (2017-2032)
 - 8.1 Argentina Viral Vector Manufacturing Market (2017-2032) by Type
 - 8.1.1 Market Overview
 - 8.1.2 Adenoviral Vectors
 - 8.1.3 Adeno-Associated Viral (AAV) Vectors
 - 8.1.4 Lentiviral Vectors
 - 8.1.5 Retroviral Vectors
 - 8.1.6 Others
 - 8.2 Argentina Viral Vector Manufacturing Market (2017-2032) by Application
 - 8.2.1 Market Overview
 - 8.2.2 Gene Therapy
 - 8.2.3 Cell Therapy
 - 8.2.4 Vaccines
 - 8.3 Argentina Viral Vector Manufacturing Market (2017-2032) by Therapeutic Area
 - 8.3.1 Market Overview
 - 8.3.2 Oncological Disorders
 - 8.3.3 Neurological Disorders
 - 8.3.4 Metabolic Disorders
 - 8.3.5 Immunological Disorders
 - 8.3.6 Others
 - 8.4 Argentina Viral Vector Manufacturing Market (2017-2032) by End User
 - 8.4.1 Market Overview
 - 8.4.2 Research Organizations
 - 8.4.3 Biotech and Pharmaceutical Companies
 - 8.4.4 Others
- 9 Mexico Viral Vector Manufacturing Market (2017-2032)
 - 9.1 Mexico Viral Vector Manufacturing Market (2017-2032) by Type
 - 9.1.1 Market Overview
 - 9.1.2 Adenoviral Vectors
 - 9.1.3 Adeno-Associated Viral (AAV) Vectors
 - 9.1.4 Lentiviral Vectors
 - 9.1.5 Retroviral Vectors
 - 9.1.6 Others
 - 9.2 Mexico Viral Vector Manufacturing Market (2017-2032) by Application
 - 9.2.1 Market Overview
 - 9.2.2 Gene Therapy
 - 9.2.3 Cell Therapy
 - 9.2.4 Vaccines

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 9.3 Mexico Viral Vector Manufacturing Market (2017-2032) by Therapeutic Area
 - 9.3.1 Market Overview
 - 9.3.2 Oncological Disorders
 - 9.3.3 Neurological Disorders
 - 9.3.4 Metabolic Disorders
 - 9.3.5 Immunological Disorders
 - 9.3.6 Others
- 9.4 Mexico Viral Vector Manufacturing Market (2017-2032) by End User
 - 9.4.1 Market Overview
 - 9.4.2 Research Organizations
 - 9.4.3 Biotech and Pharmaceutical Companies
 - 9.4.4 Others
- 10 Regulatory Framework
- 11 Patent Analysis
 - 11.1 Analysis by Type of Patent
 - 11.2 Analysis by Publication Year
 - 11.3 Analysis by Issuing Authority
 - 11.4 Analysis by Patent Age
 - 11.5 Analysis by CPC Analysis
 - 11.6 Analysis by Patent Valuation
 - 11.7 Analysis by Key Players
- 12 Funding and Investment Analysis
 - 12.1 Analysis by Funding Instances
 - 12.2 Analysis by Type of Funding
 - 12.3 Analysis by Funding Amount
 - 12.4 Analysis by Leading Players
 - 12.5 Analysis by Leading Investors
 - 12.6 Analysis by Geography
- 13 Partnership and Collaborations Analysis
 - 13.1 Analysis by Partnership Instances
 - 13.2 Analysis by Type of Partnership
 - 13.3 Analysis by Leading Players
 - 13.4 Analysis by Geography
- 14 Supplier Landscape
 - 14.1 Market Share by Top 5 Companies
 - 14.2 Lonza Group AG
 - 14.2.1 Financial Analysis
 - 14.2.2 Product Portfolio
 - 14.2.3 Demographic Reach and Achievements
 - 14.2.4 Mergers and Acquisitions
 - 14.2.5 Certifications
 - 14.3 Merck KGaA
 - 14.3.1 Financial Analysis
 - 14.3.2 Product Portfolio
 - 14.3.3 Demographic Reach and Achievements
 - 14.3.4 Mergers and Acquisitions
 - 14.3.5 Certifications

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 14.4 Thermo Fisher Scientific Inc.
 - 14.4.1 Financial Analysis
 - 14.4.2 Product Portfolio
 - 14.4.3 Demographic Reach and Achievements
 - 14.4.4 Mergers and Acquisitions
 - 14.4.5 Certifications
- 14.5 Catalent, Inc
 - 14.5.1 Financial Analysis
 - 14.5.2 Product Portfolio
 - 14.5.3 Demographic Reach and Achievements
 - 14.5.4 Mergers and Acquisitions
 - 14.5.5 Certifications
- 14.6 Danaher Corporation
 - 14.6.1 Financial Analysis
 - 14.6.2 Product Portfolio
 - 14.6.3 Demographic Reach and Achievements
 - 14.6.4 Mergers and Acquisitions
 - 14.6.5 Certifications
- 14.7 Sartorius AG
 - 14.7.1 Financial Analysis
 - 14.7.2 Product Portfolio
 - 14.7.3 Demographic Reach and Achievements
 - 14.7.4 Mergers and Acquisitions
 - 14.7.5 Certifications
- 14.8 Fujifilm Group
 - 14.8.1 Financial Analysis
 - 14.8.2 Product Portfolio
 - 14.8.3 Demographic Reach and Achievements
 - 14.8.4 Mergers and Acquisitions
 - 14.8.5 Certifications
- 14.9 Novartis AG
 - 14.9.1 Financial Analysis
 - 14.9.2 Product Portfolio
 - 14.9.3 Demographic Reach and Achievements
 - 14.9.4 Mergers and Acquisitions
 - 14.9.5 Certifications
- 14.10 Charles River Laboratories
 - 14.10.1 Financial Analysis
 - 14.10.2 Product Portfolio
 - 14.10.3 Demographic
 - 14.10.4 Mergers and Acquisitions
 - 14.10.5 Certifications
- 14.11 Laboratorios Liomont
 - 14.11.1 Financial Analysis
 - 14.11.2 Product Portfolio
 - 14.11.3 Demographic Reach and Achievements
 - 14.11.4 Mergers and Acquisitions

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

14.11.5 Certifications

15 Latin America Viral Vector Manufacturing Market - Distribution Model (Additional Insight)

15.1 Overview

15.2 Potential Distributors

15.3 Key Parameters for Distribution Partner Assessment

16 Key Opinion Leaders (KOL) Insights (Additional Insight)

17 Company Competitiveness Analysis (Additional Insight)

17.1 Very Small Companies

17.2 Small Companies

17.3 Mid-Sized Companies

17.4 Large Companies

17.5 Very Large Companies

18 Payment Methods (Additional Insight)

18.1 Government Funded

18.2 Private Insurance

18.3 Out-of-Pocket

*Additional insights provided are customisable as per client requirements.

* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.

Latin America Viral Vector Manufacturing Market Report and Forecast 2024-2032

Market Report | 2024-06-26 | 140 pages | EMR Inc.

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$3999.00
	Five User License	\$5299.00
	Corporate License	\$6299.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

☐ ** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2025-05-06"/>
		Signature	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com